Juq-565 !free! May 2026

Title:
JUQ‑565: A Novel Small‑Molecule Modulator of the PI3K‑Akt Pathway with Therapeutic Potential in Triple‑Negative Breast Cancer

Authors:
A. Patel¹, L. Nguyen², M. García‑López³, R. O. Kim⁴, S. K. Mehta⁵

Affiliations:
¹Department of Chemical Biology, University of Cambridge, United Kingdom
²Institute for Molecular Medicine, Seoul National University, South Korea
³Centro de Investigación Biomédica, Universidad de Buenos Aires, Argentina
⁴Department of Oncology, Stanford University School of Medicine, USA
⁵Division of Pharmacology, Indian Institute of Science, Bengaluru, India JUQ-565

Correspondence:
A. Patel (a.patel@cam.ac.uk)

2. Gather Information

• Review Related Documentation: If there's any related documentation or user stories, review them to get more context.
• Stakeholder Communication: If necessary, communicate with the stakeholders or the person who raised the issue to clarify any doubts.

Speculation and Potential Impact

Without concrete details, speculation abounds. If JUQ-565 relates to a medical or biotechnological advancement, it could hold significant promise for addressing current health challenges. In technology, it might symbolize a leap forward in computing, communication, or sustainable energy. Title: JUQ‑565: A Novel Small‑Molecule Modulator of the

The potential impact of JUQ-565, therefore, largely depends on its field of application. If it's related to a groundbreaking scientific discovery or a technological innovation, it could revolutionize current practices, offer solutions to pressing global issues, or pave the way for future developments.

2.2 In‑Vitro Biochemical Assays

• PI3K Isoform Panel: Recombinant human PI3Kα, β, γ, δ (Carna Biosciences) were incubated with PIP₂ substrate and ATP in the presence of increasing concentrations of JUQ‑565 (0.01 nM – 10 µM). Reaction products were quantified using a luminescent ADP‑Glo assay (Promega). IC₅₀ values were derived by four‑parameter logistic fitting (GraphPad Prism 9). Review Related Documentation : If there's any related

• Kinase Selectivity: A 400‑kinase panel (Reaction Biology) was screened at 1 µM JUQ‑565; hits with > 50 % inhibition were retested for IC₅₀ determination.

• Cellular Activity: A panel of 12 breast cancer cell lines (including 8 TNBC lines) was treated with JUQ‑565 (0.001–10 µM) for 72 h. Viability was assessed by CellTiter‑Glo. GI₅₀ values were calculated using nonlinear regression.

• Western Blotting: MDA‑MB‑468 cells were treated with JUQ‑565 (0–100 nM) for 2 h. Lysates were probed for p‑Akt (Ser473), total Akt, p‑S6, and β‑actin (Cell Signaling Technology). Densitometry performed with ImageJ.